FEATURES OF MANAGEMENT OF ELDERLY PATIENTS WITH ACUTE MYOCARDIAL INFARCTION


如何引用文章

全文:

详细

The article discusses the features of acute myocardial infarction (AMI) in elderly patients and pharmacotherapy of AMI with relation to improvement of long-term prognosis and minimization of risk of adverse events. In particular, the benefits of long-term use of acetylsalicylic acid (ASA) are considered. It was shown that the use of ASA can reduce the number of deaths by 26 in every 1000 patients with AMI during the first 35 days since its onset. Chronic usage of ASA significantly reduces the cost of primary prevention of cardiovascular complications. The use of ASA in elderly patients with AMI is justified, especially in the context of pathogenesis: experimental studies have demonstrated that this drug reduces the severity of aging-associated endothelial dysfunction. In the context of the risk of gastrointestinal hemorrhage, enteric form of ASA in a dose of 50-100 mg, which has proven efficacy (Thrombo ASS), may be safer and have special benefits specifically in elderly patients with AMI.

参考

  1. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
  2. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997;336:1621-28.
  3. Cannon CP, Gibson CM, McCabe CH, et al. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Circulation 1998;98:2805-14.
  4. GRACE Investigators. Rationale and design of the GRACE (Global Registry of Acute Coronary Events) project: a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J 2001;141:190-99.
  5. Lee PY, Alexander KP, Hammill BG, et al. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA 2001;286:708-13.
  6. Goch A, Misiewicz P, Rysz J, et al. The clinical manifestation of myocardial infarction in elderly patients. Clin Cardiol 2009;32(6):46-51.
  7. National Registry of Myocardial Infarction Web site. Available at: http://www.nrmi.org
  8. Wu AH, Parsons L, Every NR, et al. Second National Registry of Myocardial Infarction. Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol 2002;40(8):1389-94.
  9. Peterson ED, Shah BR, Parsons L, et al. Trends in quality of care for patients with acute myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. Am Heart J 2008;156(6):1045-55.
  10. Wong CK, Newby LK, Bhapker MV, et al. SYMPHONY and 2nd SYMPHONY Investigators. Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: insights from the Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes trials. Am Heart J 2007;154(2):313-21.
  11. Schuler J, Maier B, Behrens S, et al. Present treatment of acute myocardial infarction in patients over 75 years - data from the Berlin Myocardial Infarction Registry (BHIR). Clin Res Cardiol 2006;95(7):360-67.
  12. Schiele F, Meneveau N, Seronde MF, et al. Changes in management of elderly patients with myocardial infarction. Eur Heart J 2009;30(8):987-94.
  13. Austin PC, Tu JV, Ko DT, et al. Use of evidence-based therapies after discharge among elderly patients with acute myocardial infarction. CMAJ 2008;179(9):895-900.
  14. Austin PC, Tu JV, Ko DT, et al. Factors associated with the use of evidence-based therapies after discharge among elderly patients with myocardial infarction. CMAJ 2008;179(9):901-908.
  15. Goldberg RJ, Yarzebski J, Lessard D, Gore JM. Decade-long trends and factors associated with time to hospital presentation in patients with acute myocardial infarction: the Worcester Heart Attack Study. Arch Intern Med 2000;160:3217-23.
  16. White HD, Barbash GI, Califf RM, et al. Age and outcome with contemporary thrombolytic therapy: results from the GUSTO-I trial: Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries Trial. Circulation 1996;94:1826-33.
  17. Eagle KA, Goodman SG, Avezum A, et al. GRACE Investigators. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 2002;359:373-77.
  18. Krumholz HM, Gross CP, Peterson ED, et al. Is there evidence of implicit exclusion criteria for elderly subjects in randomized trials? Evidence from the GUSTO-1 Study. Am Heart J 2003;146:839-47.
  19. Krumholz HM, Friesinger GC, Cook EF, et al. Relationship of age with eligibility for thrombolytic therapy and mortality among patients with suspected acute myocardial infarction. J Am Geriatr Soc 1994;42:127-31.
  20. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-22.
  21. White HD. Thrombolytic therapy in the elderly. Lancet 2000;356:2028-30.
  22. White HD, Barbash GI, Califf RM, et al. Age and outcome with contemporary thrombolytic therapy: results from the GUSTO-I trial: Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries Trial. Circulation 1996;94:1826-33.
  23. Gore JM, Granger CB, Simoons ML, et al. Stroke after thrombolysis: mortality and functional outcomes in the GUSTO-I trial: Global Use of Strategies to Open Occluded Coronary Arteries. Circulation 1995;92:2811-28.
  24. Brass LM, Lichtman JH, Wang Y, et al. Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. Stroke 2000;31:1802-11.
  25. Alexander KP, Newby K, Armstrong PW, et al. Acute coronary care in the elderly. Part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation 2007;115:2570-89.
  26. Grines CL, Browne KF, Marco J, et al. the Primary Angioplasty in Myocardial Infarction Study Group. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993;328:673-79.
  27. Andersen HR, Nielsen TT, Rasmussen K, et al. DANAMI-2 Investigators. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003;349:733-42.
  28. Grines C, Patel A, Zijlstra F, et al. PCAT Collaborators; percutaneous transluminal coronary angioplasty. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. Am Heart J 2003;145:47-57.
  29. Boersma E. The Primary Coronary Angioplasty vs. Thrombolysis Group. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J 2006;27:779-88.
  30. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003;361:13-20.
  31. Арутюнов Г.П., Оганезова Л.Г. Острый инфаркт миокарда и почечная функция // Клиническая нефрология 2010. № 3. C. 39-44.
  32. Cardarelli F, Bellasi A, Ou FS, et al. Combined impact of age and estimated glomerular filtration rate on in-hospital mortality after percutaneous coronary intervention for acute myocardial infarction (from the American College of Cardiology National Cardiovascular Data Registry). Am J Cardiol 2009;103(6):766-71.
  33. Newsome BB., Warnock DG, McClellan WM, et al. Long-term risk of mortality and end-stage renal disease among the elderly after small increases in serum creatinine level during hospitalization for acute myocardial infarction. Arch Intern Med 2008;168(6):609-16.
  34. Goldberg A, Hammerman H, Petcherski S, et al. Inhospital and 1-year mortality of patients who develop worsening renal function following acute ST-elevation myocardial infarction. Am Heart J 2005;150(2):330-37.
  35. Jose P, Skali H, Anavekar N, et al. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. J Am Soc Nephrol 2006;17(10):2886-91.
  36. Ferrer-Hita JJ, Dominguez-Rodriguez A, Garcia-Gonzalez MJ, et al. Renal dysfunction is an independent predictor of in-hospital mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty. Int J Cardiol 2007;118(2):243-45.
  37. Goldberg A, Kogan E, Hammerman H, et al. The impact of transient and persistent acute kidney injury on long-term outcomes after acute myocardial infarction. Kidney Int 2009;76(8):900-906.
  38. Drewniak W, Snopek G, Zarukiewicz M, et al. Prognostic value of the N-terminal pro-B-type natriuretic peptide in the elderly with acute myocardial infarction. Kardiol Pol 2008;66(7):750-55.
  39. Neyou A, O'Neil B, Berman AD, et al. Determinants of markedly increased B-type natriuretic peptide in patients with ST-segment elevation myocardial infarction. Am J Emerg Med 2010 Mar 24. [Epub ahead of print]
  40. James SK, Lindahl B, Siegbahn A, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2003;108(3):275-81.
  41. Kwon TG, Bae JH, Jeong MH, et al. N-terminal pro-B-type natriuretic peptide is associated with adverse short-term clinical outcomes in patients with acute ST-elevation myocardial infarction underwent primary percutaneous coronary intervention. Int J Cardiol 2009;133(2):173-78.
  42. Шрейдер Е.В., Шахнович Р.М., Босых Е.Г., Руда М.Я. Особенности динамики и прогностическая ценность определения уровня N-аминоконцевого предшественника мозгового натрийуретического пептида при различных вариантах лечения больных с острым коронарным синдромом // Кардиология 2010. № 2. C. 15-20.
  43. Ezekowitz JA, Kaul P, Bakal JA, et al. Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. J Am Coll Cardiol 2009;53(1):13-20.
  44. White HD, Aylward PE, Huang Z, et al. VALIANT Investigators. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Circulation 2005;112(22):3391-99.
  45. Комитет экспертов ВНОК. Диагностика и лечение больных острым инфарктом миокарда с подъемом сегмента ST ЭКГ // Кардиоваскулярная терапия и профилактика 2007. № 6(8). Прил. 1. C. 415-500.
  46. Bjorck L, Wallentin L, Stenestrand U, et al. Medication in relation to ST-segment elevation myocardial infarction in patients with a first myocardial infarction: Swedish Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA). Arch Intern Med 2010;170(15):1375-81.
  47. Baigent C, Collins R, Appleby P, et al. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ 1998;316(7141):1337-43.
  48. Manson SC, Benedict A, Pan F, et al. Potential economic impact of increasing low dose aspirin usage on CVD in the US. Curr Med Res Opin 2010 Aug 26. [Epub ahead of print]
  49. Bulckaen H, Prevost G, Boulanger E, et al. Low-dose aspirin prevents age-related endothelial dysfunction in a mouse model of physiological aging. Am J Physiol Heart Circ Physiol 2008;294(4):1562-70.
  50. Wilson HL, Schwartz DM, Bhatt HR, et al. Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. Am J Ophthalmol 2004;137(4):615-24.
  51. Rahme E, Bardou M, Dasgupta K,. et al. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study. Rheumatology (Oxford) 2007;46(2):265-72.
  52. Buresly K, Eisenberg MJ, Zhang X, et al. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med 2005;165(7):784-89.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##